Krill oil and carotenoid composition, associated method and delivery system

Abstract

A medicine delivery system includes an inner capsule containing carotenoids and an outer capsule in which the inner capsule is contained within the outer capsule and the outer capsule containing a therapeutically effective amount of krill oil. In one example, the carotenoids comprise at least S, S′-astaxanthin derived from Haematococcus pluvialis , and one or more of lutein and/or trans-zeaxanthin or meso-zeaxanthin. The medicine delivery system also includes 0.5 to 8 mg of astaxanthin, 2 to 15 mg of lutein and 0.2 to 12 mg of trans-zeaxanthin contained within the inner capsule. In a specific example, the medicine delivery system includes about 4 mg of astaxanthin, about 10 mg of lutein and about 1.2 mg of trans-zeaxanthin contained within the inner capsule.

1 . A medicine delivery system comprising:
 an outer capsule containing a therapeutically effective amount of krill oil comprising phospholipid bound and triglyceride bound EPA and DHA and the krill oil comprising at least 30% total phospholipids; and   an inner capsule within the outer capsule and containing mixed carotenoids comprising at least S, S′-astaxanthin derived from Haematococcus pluvialis, and one or more of lutein and/or trans-zeaxanthin or meso-zeaxanthin, wherein the outer and inner capsules are formed to prevent mixing of the carotenoids and krill oil until after capsule ingestion.   
     
     
         2 . The medicine delivery system according to  claim 1 , further comprising 50 to 1000 mg of krill oil contained in the outer capsule. 
     
     
         3 . The medicine delivery system according to  claim 1 , further comprising 0.5 to 8 mg of astaxanthin, 2 to 15 mg of lutein and 0.2 to 12 mg of trans-zeaxanthin contained within the inner capsule. 
     
     
         4 . The medicine delivery system according to  claim 3 , further comprising about 4 mg of astaxanthin, about 10 mg of lutein and about 1.2 mg of trans-zeaxanthin contained within the inner capsule. 
     
     
         5 . A medicine delivery system comprising:
 an outer capsule containing a therapeutically effective amount of krill oil; and   an inner capsule within the outer capsule and containing carotenoids, wherein the outer and inner capsules are formed to prevent mixing of the carotenoids and krill oil until after capsule ingestion.   
     
     
         6 . The medicine delivery system according to  claim 5 , wherein the carotenoids comprise at least S, S′-astaxanthin derived from Haematococcus pluvialis, and one or more of lutein and/or trans-zeaxanthin or meso-zeaxanthin. 
     
     
         7 . The medicine delivery system according to  claim 6 , further comprising 0.5 to B mg of astaxanthin, 2 to 15 mg of lutein and 0.2 to 12 mg of trans-zeaxanthin contained within the inner capsule. 
     
     
         8 . The medicine delivery system according to  claim 7 , further comprising about 4 mg of astaxanthin, about 10 mg of lutein and about 1.2 mg of trans-zeaxanthin contained within the inner capsule. 
     
     
         9 . The medicine delivery system according to  claim 5 , wherein the krill oil contains phospholipid bound and triglyceride bound EPA and DHA and the krill oil contains at least 30% total phospholipids. 
     
     
         10 . The medicine delivery system according to  claim 5 , further comprising 50 to 1000 mg of krill oil contained in the outer capsule. 
     
     
         11 . A composition comprising a therapeutically effective amount of a synergistic multi-ingredient composition of krill oil containing phospholipid bound and triglyceride bound EPA and DHA in which the krill oil contains at least 30% total phospholipids, and mixed carotenoids comprising at least S, S′-astaxanthin derived from Haematococcus pluvialis that is reacted with the krill oil, and one or more of lutein and/or trans-zeaxanthin or meso-zeaxanthin. 
     
     
         12 . The composition according to  claim 11 , further comprising 0.5 to 8 mg of astaxanthin, 2 to 15 mg of lutein and 0.2 to 12 mg of trans-zeaxanthin. 
     
     
         13 . The composition according to  claim 12 , further comprising about 4 mg of astaxanthin, about 10 mg of lutein and about 1.2 mg of trans-zeaxanthin. 
     
     
         14 . The composition according to  claim 11 , further comprising 50 to 100 mg of krill oil. 
     
     
         15 . A composition comprising a therapeutically effective amount of a synergistic multi-ingredient composition of krill oil and carotenoids that are reacted with the krill oil. 
     
     
         16 . The composition according to  claim 15 , further comprising 50 to 1000 mg of krill oil. 
     
     
         17 . The composition according to  claim 15 , wherein the krill oil comprises phospholipid bound and triglyceride bound EPA and DHA in which said krill oil contains at least 30% total phospholipids. 
     
     
         18 . The composition according to  claim 15 , wherein the catotenoids comprise at least S, S′-astaxanthin derived from Haematococcus pluvialis that had reacted with the krill oil, and one or more of lutein and/or trans-zeaxanthin or meso-zeaxanthin. 
     
     
         19 . The composition according to  claim 18 , further comprising 0.5 to 8 mg of astaxanthin, 2 to 15 mg of lutein and 0.2 to 12 mg of trans-zeaxanthin. 
     
     
         20 . The composition according to  claim 19 , further comprising about 4 mg of astaxanthin, about 10 mg of lutein and about 1.2 mg of trans-zeaxanthin. 
     
     
         21 . A method of treating an individual by administrating a therapeutically effective amount of a synergistic multi-ingredient composition of krill oil and carotenoids and reacting the carotenoids in vivo with the krill oil. 
     
     
         22 . The method according to  claim 21 , further comprising administering carotenoids comprising at least S, S′-astaxanthin derived from Haematococcus pluvialis, and one or more of lutein and/or trans-zeaxanthin or meso-zeaxanthin. 
     
     
         23 . The method according to  claim 22 , further comprising administering 0.5 to 8 mg of astaxanthin, 2 to 15 mg of lutein and 0.2 to 12 mg of trans-zeaxanthin. 
     
     
         24 . The method according to  claim 23 , further comprising administering about 4 mg of astaxanthin, about 10 mg of lutein and about 1.2 mg of trans-zeaxanthin. 
     
     
         25 . The method according to  claim 21 , further comprising administering krill oil containing phospholipid bound and triglyceride bound EPA and DHA, the krill oil comprising at least 30% total phospholipids. 
     
     
         26 . The method according to  claim 21 , further comprising administering 50 to 1000 mg of krill oil.